Myriad Genetics Inc (MYGN)
Myriad Genetics, Inc. is a biotechnology company focused on molecular diagnostics and precision medicine. The company develops and commercializes tests used in oncology, women’s health, and pharmacogenomics. Its portfolio includes hereditary cancer and companion diagnostic tests such as MyRisk, BRACAnalysis CDx, and MyChoice CDx, along with products used to assess cancer aggressiveness, including Prolaris and EndoPredict. Myriad also offers prenatal and carrier screening tests such as Prequel and Foresight, as well as GeneSight for psychotropic medication guidance. The company has collaborations with Illumina, M.D. Anderson Cancer Center, Mayo Foundation, Children’s Medical Center in Boston, Institut Curie and INSERM, and Eurobio Scientific. Myriad Genetics was founded in 1991 and is based in Salt Lake City, Utah.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MYGN
|
$5.09
|
30.8% Upside
|
Undervalued
|
$3.37
|
-13.5% Downside
|
Fair
|
Good
|
0.0%
|
November 9, 2026
|
1.3x
|
0.5x
|
372.1 M
|
491.3 M
|
36.1%
|
83.0%
|
-1.5
|
6.5%
|
